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ABSTRACT
The small non-coding VTRNA1-1 (vault RNA 1–1) is known to confer resistance to apoptosis in several 
malignant cell lines and to also modulate the macroautophagic/autophagic flux in hepatocytes, thus 
highlighting its pro-survival role. Here we describe a new function of VTRNA1-1 in regulating in vitro 
and in vivo tumor cell proliferation, tumorigenesis and chemoresistance. Knockout (KO) of VTRNA1-1 
in human hepatocellular carcinoma cells reduced nuclear localization of TFEB (transcription factor 
EB), leading to a downregulation of the coordinated lysosomal expression and regulation (CLEAR) 
network genes and lysosomal compartment dysfunction. We demonstrate further that impaired 
lysosome function due to loss of VTRNA1-1 potentiates the anticancer effect of conventional che-
motherapeutic drugs. Finally, loss of VTRNA1-1 reduced drug lysosomotropism allowing higher 
intracellular compound availability and thereby significantly reducing tumor cell proliferation 
in vitro and in vivo. These findings reveal a so far unknown role of VTRNA1-1 in the intracellular 
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Introduction
A new class of small non-coding RNA (ncRNA), named 
vault RNA (vtRNA), was discovered in 1986 in the Rome 
lab [1]. Vault RNAs are integral components of the large 
13-MDa vault particle, a hollow barrel-shaped ribonucleo-
protein (RNP) complex, consisting of multiple copies of 
three proteins: MVP (major vault protein), PARP4/vPARP 
(poly(ADP-ribose) polymerase family member 4) and TEP1 
(telomerase associated protein 1) [2]. Notably, only a minor 
fraction of their cellular transcript is associated with the 
vault particles [3,4] hinting to complex-independent func-
tions. Vault RNAs are short POLR3 (RNA polymerase III) 
transcripts with a length varying between about 80 and 150 
nucleotides (nt). In humans, four vtRNA paralogs have 
been identified, VTRNA1-1, VTRNA1-2, VTRNA1-3 and 
VTRNA2-1 [4,5]. vtRNAs have been suggested to be 
involved in a multitude of functions including cell prolif-
eration [6,7], apoptosis [8], autophagy [9], serving as 
microRNA precursors [10] and have also been linked to 
chemotherapy resistance [11,12]. Many of these findings are 
compatible with the hypothesis that altered vault RNA 
expression is associated with tumorigenesis. Recently, we 
demonstrated that the VTRNA1-1 paralog protects various 
human cancer cell lines from undergoing apoptosis in 
a vault particle-independent manner [8,13]. Yet, the exact 
function and mechanism of action of vault RNAs remains 
undeciphered in molecular terms.
Other classes of small ncRNAs, such as microRNAs 
(miRNA) and tRNA-derived RNAs (tdRs) have also been 
linked to tumorigenesis. miRNA levels were found to be 
altered in all cancer types studied [14] and have been 
suggested to function as tumor suppressors or oncogenes 
(oncomiRs) [15]. miRNAs seem to exert multifaceted 
functions on tumor progression, modulating tumor 
growth, metastatic potential, chemoresistance and regula-
tion of metabolism [16,17]. Similarly, tdRs have been 
identified to be significantly upregulated under various 
stress conditions and therefore have garnered much atten-
tion in the recent years [18–21]. This newly discovered 
class of ncRNAs has been shown to influence cancer 
development by modulating global translation via regulat-
ing the expression of genes coding for ribosomal compo-
nents [22], interacting with RNA binding proteins [23], by 
regulating kinase activity [24] and promoting cell prolif-
eration [25]. It is evident that small ncRNAs are important 
regulatory molecules orchestrating gene expression that 
can either drive or prevent oncogenic processes and there-
fore possess potential as prognostic biomarkers or putative 
drug targets for cancer treatment.
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Autophagy is among the biological processes that have 
been recently connected to vault RNA levels [9]. Autophagy 
is an evolutionarily conserved degradation pathway activated 
by cellular stress [26]. Basal autophagy is essential for the 
degradation and the recycling of proteins and organelles. 
Especially during stress conditions an effective autophagy 
machinery is beneficial for cell survival [26]. Damaged orga-
nelles and proteins are taken up by autophagosomes which 
fuse with lysosomes for degradation [27]. Lysosomes are a key 
entity of the cellular digestive system and their function 
requires the concerted action of hydrolases, the acidification 
machinery and lumenal protective membrane proteins [28]. 
Lysosome biogenesis and function are closely coordinated by 
TFEB (transcription factor EB). TFEB orchestrates the coor-
dinated lysosomal expression and regulation (CLEAR) net-
work genes, involved in lysosomal biogenesis, lysosome-to- 
nucleus signaling and lipid catabolism [28]. The acidic envir-
onment of the lysosomes is a double-edged sword for che-
motherapy. Numerous anti-tumor drugs, due to their 
formulation as a weak-base and hydrophobicity, can be 
sequestered into the lysosomal lumen, a phenomenon 
known as lysosomotropism, thus reducing drug-sensitivity 
and inducing chemoresistance [29].
Here, we describe a novel pro-survival function of 
VTRNA1-1/vtRNA1-1 in regulating in vitro and in vivo 
tumor cell proliferation, tumorigenesis and chemoresistance, 
via its newly disclosed role in supporting the function of 
lysosomes. We showed that VTRNA1-1 knockout (KO) in 
human hepatocellular carcinoma (HCC) cells, leads to lyso-
somal compartment dysfunction by inhibiting TFEB nuclear 
translocation thus resulting in a downregulation of the 
CLEAR network genes. We observed that VTRNA1-1 deple-
tion resulted in an increased activation of the MAPK (mito-
gen-activated protein kinase) cascade, MAPK1/ERK2-MAPK3 
/ERK1, responsible for TFEB inactivation and cytoplasmic 
retention. Finally, we demonstrated that lack of VTRNA1-1 
reduces drug lysosomotropism and significantly inhibits 
tumor cell proliferation in vitro and in an in vivo mouse 
model. These findings reveal a role of VTRNA1-1 in support-
ing the function of the intracellular catabolic compartment in 
human hepatocellular carcinoma cells and highlight its impor-
tance in lysosome-mediated chemotherapy resistance.
Results
VTRNA1-1 plays a crucial role in tumor cell proliferation 
and tumorigenesis
The anti-apoptotic effect of VTRNA1-1/vtRNA1-1 has been 
the subject of intensive studies in our laboratory [8,13] and 
lead us to hypothesize about its involvement in tumorigenesis 
and cancer progression. To test the influence of VTRNA1-1 
expression on tumor cell proliferation and colony formation 
in vitro, we used the human hepatocellular carcinoma cell 
lines Huh-7 (WT), and Huh-7 VTRNA1-1 KO (Figure 1A). 
We found that proliferation and colony formation were sig-
nificantly reduced in Huh-7 VTRNA1-1 KO cells (Figure 1B- 
D). Re-introducing the VTRNA1-1 gene could fully rescue cell 
proliferation in these complementation cells (Figure 1A, C). 
Likewise, the colony formation assay showed a similar trend 
upon VTRNA1-1 complementation (Figure 1D). The lack of 
VTRNA1-1 seems to suggest an important role of this ncRNA 
in tumor cell viability and proliferation. To further assess the 
effects of vtRNA1-1 on the tumor growth using an in vivo 
subcutaneous xenograft mouse model, we injected Huh-7 cells 
into mice and allowed to develop measurable tumors. 
Consistent with our in vitro results, the growth was signifi-
cantly reduced in the VTRNA1-1 KO-transplanted tumors 
compared to the WT (Figure 1E, F).
Interestingly, VTRNA1-1 expression seems to be also 
modulated in human derived primary hepatocytes 
(Figure S1A). In culture, primary hepatocytes are unable 
to proliferate and progressively de-differentiate from their 
cell-specific functions [30,31]. Interestingly, we observed 
a significant increase in VTRNA1-1 expression in hepato-
cyte cultures for up to 14 days (Figure S1A) while hepa-
tocytes still maintained their differentiated state (Figure 
S1B). Hepatocytes in culture are known for spontaneously 
activating apoptosis pathways [32,33]. Consistently, we 
detected PARP1 (poly(ADP-ribose) polymerase 1) cleavage 
already at day 0 (before seeding) together with an 
increased expression of BCL2 (BCL2 apoptosis regulator) 
(Figure S1C), hinting at the already described activation 
of an anti-apoptotic cellular response [34]. Thus, increased 
VTRNA1-1 expression might be similarly involved in pro- 
survival pathways.
These observations reveal that the cellular levels of 
VTRNA1-1/vtRNA1-1 contribute to proliferation in immorta-
lized cell lines and are modulated in response to stresses in 
primary hepatocytes. All together our data indicate that 
vtRNA1-1 plays a key role in tumor cells proliferation and 
tumorigenesis.
Defective lysosome function impairs autophagy-mediated 
clearance in VTRNA1-1 KO cells
Because VTRNA1-1 levels have been reported previously to 
affect apoptosis [8,13] and autophagy [9], we next asked the 
question how and if these cellular processes are linked via 
VTRNA1-1 expression in hepatocytes. Huh-7 sensitivity 
toward apoptosis was not affected by VTRNA1-1 depletion, 
since upon staurosporine (STS) treatment, a broad-spectrum 
protein kinase inhibitor inducing apoptosis, the IC50 values 
were similar for both WT and VTRNA1-1 KO cell lines 
(Figure 2A). In agreement cleavage of pro-apoptotic PARP1 
was not observed or was negligible in these cells (Figure 2B). 
These results fit with the observation that Huh-7 are remark-
ably resistant to apoptosis even after treatment with STS [35]. 
Similar results were obtained using the pro-apoptotic DNA- 
damaging anticancer drug doxorubicin (Figure S2A) as well 
as during high stress culture conditions (serum-deprived cul-
ture medium) where KO of VTRNA1-1 actually slightly 
enhances cell survival compared to WT (Figure S2B). This 
is in stark contrast to the effects seen in HeLa cells, where 
staurosporine treatment and starvation increase apoptotic 
rates and induces PARP1 cleavage (Figure 2B and [13]).
A recent study suggested that VTRNA1-1 acts as 
a regulator of autophagy by interacting with SQSTM1/p62 
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Figure 1. VTRNA1-1/vtRNA1-1 plays a crucial role in tumor cell proliferation and tumorigenesis. (A) Total RNA was extracted from Huh-7 cells and analyzed by 
northern blotting to confirm successful VTRNA1-1 complementation in Huh-7 KO cells. RNA5-8S5 (RNA, 5.8S ribosomal 5) serves as internal loading control. (B) Mean 
± SD relative proliferation of Huh-7 WT, KO and complementation cells was measured with the MTT assay. Values were normalized to day 1, n = 3. (C) Three-day cell 
proliferation (cells/ml) by automated cell counter. Values were normalized to day 1, n = 5 ± SD. (D) Clonogenic assay: data are expressed as the mean values of three 
independent experiments ± SD. (E) Tumor volume ± SEM of Huh-7 subcutaneous xenografts mouse model (WT n = 4 and KO n = 5). (F) Huh-7 subcutaneous 
xenografts immunohistochemistry for MKI67. Counterstain: hematoxylin. Scale bar: 50 μm. The graphs show the mean percentage ± SD of MKI67-positive cell/area 
per tumor/mouse (five random fields were used for the analysis per tumor/mouse). P values < 0.05 were considered statistically significant and are indicated as 
follows: *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; ns, not significant.
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Figure 2. Defective lysosome function impairs autophagy-mediated clearance in VTRNA1-1 KO cells. (A) IC50 values of Huh-7 WT and KO cells after 24 h of 
staurosporine treatment. (B) Representative immunoblots for PARP1 (FL, full-length) and ACTB/β-actin in Huh-7 and HeLa cells after Staurosporine IC30 treatment (24  
h, 5 μM). HeLa cells were used as control for apoptosis induction. (C) Representative immunoblots for LAMP1, SQSTM1/p62, LC3B-I, LC3B-II (o. e., overexposed) and 
ACTB/β-actin in Huh-7 cells under complete culture medium (10% FBS – Ctrl) and treatment with chloroquine (CQ – 20 μM, 4 h) or bafilomycin A1 (BafA, 100 nM, 4 h). 
(D) Top panel, mean ± SD of lysosomal pH values measured by flow cytometry in Huh-7 pre-incubated in culture medium supplemented with FITC-dextran (0.1 mg/ 
mL, 72 h) followed starvation (0.1% FBS) for 24 h and high starvation (HS, with low glucose, without amino acids and FBS) for 6 h. n = 3. Bottom panel, illustrative 
histograms from flow cytometry showing the shift of FITC-dextran emission wavelength. (E) Representative immunoblots for GST-BHMT of total lysate obtained from 
Huh-7 cells transiently transfected with the GST-BHMT construct and either maintained in complete culture media or starving media supplemented with leupeptin 
and E64d and without essential amino acids and FBS for 6 h. Red Ponceau staining served as loading control. P values < 0.05 were considered statistically significant 
and are indicated as follows: *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; ns, not significant.
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(sequestosome 1), which is involved in targeting substrates of 
the autophagy machinery, preventing its self-oligomerization 
in Huh-7 cells [9]. As already shown by Horos et al., 
VTRNA1-1-dependent impairment of the autophagic flux 
can be detected by treating Huh-7 cells with the two late- 
stage autophagy inhibitors, chloroquine (CQ) and bafilomycin 
A1 (BafA). Western blot analysis revealed an increased 
amount of MAP1LC3B/LC3 (microtubule- associated protein 
1 light chain 3 beta) expression in KO cell lines compared to 
WT (Figure 2C, S2C). Conversion of LC3B-I to LC3B-II is the 
hallmark for autophagosome formation. Interestingly, we 
detected a pronounced LC3B-II protein accumulation in 
cells lacking VTRNA1-1 already at basal level, under normal 
culture conditions, suggesting that loss of this ncRNA induces 
autophagy impairment (Figure 2C). Of note, no significant 
changes in SQSTM1/p62 levels were apparent under control 
conditions in the absence of VTRNA1-1 (Figure 2C).
Autophagosomes are intermediate structures in a very 
dynamic process, where their intracellular localization results 
from a balance between their generation and their conversion 
rate into autolysosomes [36]. Thus, autophagosome accumulation 
may derive from either autophagy induction or impaired lysoso-
mal clearance [28]
To identify the phenomenon causing autophagosome 
accumulation in VTRNA1-1 KO cells, we first aimed to 
examine lysosomal compartment structural proteins focus-
ing on the expression levels of LAMP1 (lysosomal asso-
ciated membrane protein 1). Interestingly, LAMP1 levels 
were increased, together with an enhanced expression of 
its hyperglycosylated (H-Glyc) form only in VTRNA1-1 
KO cells (Figure 2C). Further, in variance to WT cells 
we found that CQ- and BafA-induced upregulation of 
LAMP1, a clear sign of a larger accumulation of undi-
gested autolysosomes, was not detectable in the absence of 
VTRNA1-1 (Figure 2C). An increased expression of 
H-Glyc LAMP1 has been reported to be linked with 
intrinsic lysosomal compartment instability [37]. 
Moreover, in addition to lysosomal compartment stability, 
lysosome-mediated cellular clearance processes require the 
concerted action of hydrolases and the intralumenal acid-
ification machinery [28]. Interestingly, in VTRNA1-1 KO 
cells we detected a significant increase in lysosomal pH 
toward more alkaline values (Figure 2D). Taking advan-
tage of the GST-BHMT assay, previously developed for 
measuring autophagic degradation capabilities [38], we 
next assessed the lysosomal proteolytic activity in the 
cells. In line with our previous observations, the ability 
of lysosomes to degrade GST-BHMT was markedly 
reduced in absence of VTRNA1-1, indicating an impaired 
lysosomal proteolytic activity (Figure 2E). Conversely, in 
HeLa cells, where VTRNA1-1 was shown to confer apop-
tosis resistance [8,13], neither changes in lysosomal pH 
nor in lysosomal proteolytic activity were apparent when 
VTRNA1-1 was depleted (Figure S2D and E).
Collectively, our data demonstrate that VTRNA1-1 has 
a crucial role in Huh-7 in modulating lysosomal function, 
especially for regulating their intralumenal pH and proteolytic 
activity.
VTRNA1-1 levels influence TFEB nuclear translocation 
and affect TFEB-driven CLEAR network gene expression
Lysosomal function is closely monitored to respond and adapt 
to environmental stimuli by its master TFEB regulator. Under 
basal conditions, TFEB is located in the cytoplasm and under 
specific stimuli, such as starvation, it is rapidly translocated 
into the nucleus. The cellular localization and activity of TFEB 
are mainly controlled by phosphorylation, which depends 
predominantely on MTORC1 and MAPK1/ERK2 [39,40]. To 
gain further mechanistic insight into the molecular events 
regulating TFEB activation, we tested whether its upstream 
regulators might be influenced by VTRNA1-1 expression. 
While we did not observe any difference in MTOR phosphor-
ylation (Figure 3A), VTRNA1-1 depletion resulted in a clear 
basal increase of MAPK pathway activation (Figure 3B and 
S3A). We observed a higher phosphorylation level of 
MAPK1/3, its upstream kinases MAP2K1/MEK1-MAP2K 
/MEK2 as well as RPS6KA1/90RSK (ribosomal protein S6 
kinase A1), its downstream target (Figure 3B and S3A). 
Importantly, the elevated markers of phosphorylation 
returned to WT-levels in the complementation cells (Figure 
3B and S3A) thus suggesting that re-introducing VTRNA1-1 
restores signaling. Surprisingly, the MAPK pathway was also 
regulated in HeLa VTRNA1-1 KO cells, but in an opposite 
manner (Figure S3B). Our data suggests that the loss of 
VTRNA1-1 leads to a hyperactivation of MAPK1/3, which 
might in turn prevent TFEB nuclear translocation. We indeed 
found the amount of nuclear TFEB accumulation to be sig-
nificantly lower in KO cells compared to the WT (Figure 3C 
and S3C). Other transcription factors of the same family 
known to regulate starvation-induced lysosomal biogenesis 
and autophagy [41,42] were either lowly expressed in Huh-7 
and thus below the western blot detection limit (MITF), or 
did not show changes in protein expression or altered locali-
zation upon VTRNA1-1 removal (TFE3) (Figure 3D). These 
findings are in accordance with a previous study demonstrat-
ing no nuclear translocation of TFE3 or MITF in Huh-7 cells 
under the applied starvation conditions [43]. Therefore, our 
results reveal VTRNA1-1 levels to specifically influence TFEB 
as the major transcription factor for lysosome biogenesis.
TFEB orchestrates lysosomal expression and regulation 
(CLEAR) network genes, involved in lysosomal biogenesis, 
lysosome-to-nucleus signaling and lipid catabolism [28]. 
Therefore, we analyzed the expression of known TFEB target 
genes in KO cells compared to WT at basal level and under 
serum-deprived culture conditions, where especially tumor 
cells more heavily rely on their intracellular catabolic machin-
ery. In fact, the recycling of intracellular constituents provides 
alternative energy sources during periods of metabolic stress 
to maintain homeostasis and viability [44]. While the mRNA 
levels of TFEB remained unchanged, its target genes, such as 
LAMP1, CLCN7 (chloride voltage-gated channel 7), CTSD 
(cathepsin D) and ATP6V0D2 (ATPase H+ transporting V0 
subunit d2) were downregulated in the absence of VTRNA1-1 
(Figure 3E). Upon complementation, Huh-7 cells restored 
VTRNA1-1 levels (Figure 1A), concomitantly with an 
increased expression of CLEAR network genes (Figure 3E). 
Overexpressing a TFEB gain-of-function mutant with 
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pronounced nuclear localization characteristics ([45] and 
Figure S3D) in the VTRNA1-1 KO cells rescued expression 
of CLEAR network genes (Figure S3E). These observations 
substantiate the interdependence of VTRNA1-1 expression, 
TFEB nuclear localization and lysosome activity. 
Consistently, we also confirmed that the CLEAR network 
genes were downregulated in tumors in VTRNA1-1 KO- 
injected mice compared to the WT control (Figure 3E), 
Figure 3. VTRNA1-1/vtRNA1-1 plays a key role in TFEB nuclear translocation and TFEB-driven CLEAR network genes expression. (A) Representative immunoblots for 
p-MTOR, total MTOR and GAPDH in Huh-7 WT and VTRNA1-1 KO cells under normal culture conditions (10% FBS). (B) Left, representative immunoblots for p-MAPK1/ 
ERK2-MAPK3/ERK1, total MAPK1/3 and ACTB/β-actin in Huh-7 WT, VTRNA1-1 KO and complementation cells under normal culture conditions (10% FBS). Right, 
quantification of p-MAPK1/3 obtained by normalizing the p-MAPK1/3 and total MAPK1/3 levels by ACTB/β-actin followed by the ratio of p-MAPK1/3 over total 
MAPK1/3. Values are expressed as the mean values of three (for WT and KO) or two (for complementation) independent experiments ± SD normalized to WT level. 
(C) Left, representative nuclear/cytoplasm fractionation immunoblots for TFEB, TUBA/α-tubulin, histone H3 in Huh-7 WT and VTRNA1-1 KO cells under high starvation 
for 3 h. Right, quantification of TFEB nuclear levels normalized to histone H3. Values are expressed as the mean values of three independent experiments ± SD. (D) 
Representative nuclear-cytoplasm fractionation immunoblots for TFE3, GAPDH, histone H3 in Huh-7 WT and VTRNA1-1 KO cells under high starvation for 3 h. (E) Real- 
time qPCR data (mean ± SEM) of TFEB, LAMP1, CTSD, CLCN7 and ATP6V0D2 mRNA levels in Huh-7 VTRNA1-1 KO cells grown under complete medium (10% FBS – Ctrl) 
and starving culture conditions (0.1% FBS) for 24 h, normalized to Huh-7 WT (n = 3) and VTRNA1-1 KO-derived tumors normalized to WT-transplanted ones (WT 
n = 4, KO n = 9). (F) Real-time qPCR mean ± SEM data of SQSTM1/p62 in Huh-7 KO cells and derived tumors normalized to Huh-7 WT and WT-transplanted tumors 
respectively. P values < 0.05 were considered statistically significant and are indicated as follows: *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; ns, not 
significant.
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indicating that the previously observed altered lysosome func-
tion in the VTRNA1-1 KO cells (Figure 2C) can be attributed 
to the downregulation of CLEAR gene expression. Of note, 
SQSTM1/p62 expression is also under the transcriptional 
control of TFEB [46] and in fact, in line with our previous 
findings, its mRNA levels were significantly downregulated in 
VTRNA1-1 KO cells compared to WT in cell culture as well as 
in the in vivo mouse model (Figure 3F).
In summary these data provided evidence that 
VTRNA1-1 plays a role in establishing lysosome function, 
where its absence lead to a marked loss of autolysosome 
proteolytic activity, decreased TFEB nuclear translocation 
and subsequent reduced expression of CLEAR network 
genes.
Removal of VTRNA1-1 potentiates the cytotoxicity of 
sorafenib in vitro and in vivo
Our data provide evidence that loss of VTRNA1-1/ 
vtRNA1-1 interferes with lysosome function, thus leading 
to a deficiency in the autophagic machinery. Weak base 
anticancer compounds can be sequestered in the acidic 
lumen of lysosomes by cation trapping and consequently 
are no longer able to reach their target, thereby reducing 
their effectiveness [47]. It has been reported that the 
cytotoxic potential of sorafenib (SF), the first-line treat-
ment option for advanced hepatocellular carcinoma 
patients and a known tyrosine kinase inhibitor of the 
MAPK pathway [48], is significantly decreased due to its 
passive lysosomal compartment trapping [37]. Therefore, 
we next investigated if loss of VTRNA1-1 leads to lysoso-
mal malfunction and thus consequently to increased drug 
sensitivity. When treated with the IC30 dose of SF, Huh-7 
KO cells showed a significantly decreased viability com-
pared to WT cells after treatment (Figure 4A). This 
increased SF cytotoxicity indeed depends on VTRNA1-1 
levels since the rescued cell line behaved similarly to the 
WT cells (Figure 4A). Interestingly, we found that SF 
markedly downregulates MAPK1/3 phosphorylation in 
a time-dependent manner in Huh-7 KO cells compared 
to the WT (Figure 4B), suggesting a higher amount of 
drug being able to reach its intracellular molecular target 
due to a decreased lysosomotropism. On the other hand, 
the lysosomotropic compound LLOMe (L-leucyl-L-leucine 
Figure 4. Removal of VTRNA1-1 potentiates the cytotoxicity of sorafenib in vitro and in vivo. (A) Mean ± SD relative viability of Huh-7 WT, KO and complementation 
cells, after sorafenib IC30 treatment (24 h, 14 μM) measured with the MTT assay. Values were normalized to untreated cells, n = 3. (B) Representative immunoblots for 
p-MAPK1/3, total MAPK1/3 and GAPDH in Huh-7 WT and VTRNA1-1 KO cells in presence or absence of sorafenib (5 μM) as indicated. (C) Tumor volume of Huh- 
7-transplanted xenografts mice treated with vehicle and sorafenib (SF – 100 mg/kg – daily oral gavage) for 14 days (SF n = 6/group; vehicle WT n = 4, KO n = 5). 
P values < 0.05 were considered statistically significant and are indicated as follows: *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; ns, not significant.
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methyl ester), which is an acidic pH-driven lysosome- 
specific membrane damage inducer, showed a markedly 
reduced cytotoxicity in VTRNA1-1 KO cells (Figure 
S4A). Huh-7 WT cells viability was more strongly 
decreased compared to VTRNA1-1 KO cells after LLOMe 
administration (Figure S4A). We observed a significantly 
lower LLOMe-induced lysosomal pH alkalinization in 
Huh-7 VTRNA1-1 KO cells compared to the WT (Figure 
S4B) further confirming a weaker LLOMe lysosomal com-
partment tropism and trapping of LLOMe, mainly due to 
the previously shown elevated alkaline intralumenal pH 
observed for the KO cells (Figure 2D). Corroborating 
our in vitro data, SF treatment significantly impaired 
tumor growth and progression in the Huh-7 KO- 
transplanted mice as compared to animals transplanted 
with the WT control cells (Figure 4C).
These data exhibit a role of VTRNA1-1 in lysosomal 
compartment functionality, which seems to involve in the 
positive modulation of the pro-tumorigenic MAPK cas-
cade activation (Figure 5). Cumulatively we found that 
VTRNA1-1 plays a significant role in determining the 
intracellular fate and potency of lysosomotropic com-
pounds and thus affects their molecular target site distri-
bution and antitumor effectiveness.
Discussion
The human genome encodes on chromosome 5 four vault 
RNA paralogs, VTRNA1-1, VTRNA1-2, VTRNA1-3 and 
VTRNA2-1 [5]. These ncRNAs are around 100 residues long 
and they received their name based on an early observation 
that they are integral to the vault particle, a gigantic hollow 
RNP with a molecular mass of 13 MDa [1]. Despite decades of 
dedicated research, the biological function of the vault particle 
or the vault RNAs remained enigmatic [2,49]. More recently, 
it was demonstrated that only a minor fraction of vault RNA 
is actually associated with the vault complex [4,50] thus sug-
gesting cellular functions of these ncRNAs beyond the vault 
complex. Accumulating evidence reveals a key role of the 
small non-coding VTRNA1-1/vtRNA1-1 in conferring cellular 
resistance against cell death via chemoresistance [7,12], viral 
defense and apoptosis [4,8,13,51]. This led us to further 
investigate the involvement of VTRNA1-1 in tumorigenesis 
and cancer progression. In agreement with its previously 
described function, we observed a modulation of VTRNA1-1 
expression in response to apoptosis induced by physical and 
mechanical stress in primary human hepatocytes (Figure S1 
A, C). We further describe that VTRNA1-1 is involved in 
tumor cell proliferation, tumorigenesis and chemoresistance, 
Figure 5. Model for lysosome and autophagy mediated clearance regulation. In VTRNA1-1/vtRNA1-1 WT cells low MAPK1/3 phosphorylation level allows TFEB nuclear 
translocation leading to CLEAR network genes expression and ensuring intracellular catabolic compartment stability and function (left). Reduced VTRNA1-1 levels 
(right) lead to the hyperphosphorylation of MAPK1/3 and TFEB, and consequently to its reduced nuclear translocation, leading to a downregulation of the CLEAR 
network genes and lysosomal compartment dysfunction.
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via its newly described role in supporting the function of the 
intracellular catabolic machinery (Figures 1, Figures 2D-E and 
4A-C). However, we did not observe that the sensitivity of 
Huh-7 cells to apoptosis was altered by the lack of VTRNA1-1 
(Figure 2A, B and Figure S2A, B). This is in clear contrast to 
several other immortalized cell lines, such as the Burkitt 
Lymphoma cell lines (BL2, BL41), the breast cancer model 
HS578T, the human embryonic kidney cells (HEK293), the 
lung carcinoma cells A549 and HeLa cells [8,13]. It is safe to 
conclude that high VTRNA1-1 levels are correlated with pro- 
survival characteristics in numerous human cell lines of dif-
ferent tissue origins (Figure S5). Thus, it is possible that the 
well-documented pro-survival biological function of 
VTRNA1-1 manifests itself differently and is cell line or tissue 
dependent and a generalized mechanism of VTRNA1-1 
should not be based on data obtained in one cellular system. 
A recent study in Huh-7 cells reported that VTRNA1-1 was 
able to contribute in the regulation of the autophagic flux, by 
directly interacting with the autophagy receptor protein 
SQSTM1/p62 [9]. In our study, we were able to confirm that 
the loss of VTRNA1-1 leads to elevated LC3B-II levels sug-
gesting autophagosome accumulation (Figure 2C and Figure 
S2C). Previously these observations were interpreted as evi-
dence for an increase of the autophagic flux in the absence of 
VTRNA1-1 [9]. Our in vitro and in vivo experiments provide 
further insight into VTRNA1-1 biology and elaborate the 
suggested role of SQSTM1/p62 as post-transcriptional regu-
lator of autophagy [9]. Although the decreased steady-state 
level of SQSTM1/p62 was initially attributed to the lost inter-
action with VTRNA1-1 [9], we found that depletion of 
VTRNA1-1 resulted in transcriptional downregulation of sev-
eral catabolism-related genes, including also SQSTM1/p62 
(Figure 3E and F). Our data demonstrated that reduced 
expression of SQSTM1/p62 is transcriptionally controlled 
and it is not necessarily dependent on its interaction with 
VTRNA1-1.
Lysosomes and autophagy are two tightly linked and evo-
lutionarily conserved processes that provide a constant supply 
of cellular energy mainly through recycling of damaged orga-
nelles and proteins [27]. As previously described by Horos 
et al., VTRNA1-1 depletion leads to mature autophagosomes 
accumulation, suggesting an increased autophagic flux [9]. 
However, autophagosomes accumulation, in the absence of 
any specific chemical modulator of the flux progression, may 
come from either autophagy induction or impaired lysosomal 
autophagy-mediated clearance. Lysosomes are intracellular 
vesicles responsible for such catabolic and clearance processes 
in cell homeostasis, and their function requires the concerted 
action of hydrolases, acidification pumps for maintaining 
acidic the intralumenal pH and lysosomal membrane proteins 
to ensure the integrity of this specific vesicular compartment 
[28]. Investigating the lysosome-mediated clearance process, 
we demonstrated that deletion of VTRNA1-1 caused an alka-
linization of the intralumenal lysosomal pH, leading to 
a marked impairment of their proteolytic and degradative 
activity (Figure 2D, E). LAMPs are structural proteins impor-
tant for maintaining lysosomal membrane integrity and sta-
bility by segregating the acidic environment of the lumen 
from the rest of the cell [52]. Under normal conditions, 
LAMP1 glycosylation protects the inner lysosomal membrane 
from cleavage and degradation from the low pH of the intra-
lumenal environment [53]. Knockout of VTRNA1-1 leads to 
an impairment of CQ- and BafA-induced LAMP1 accumula-
tion (Figure 2C). Additionally, an already stressed and intrin-
sically instable status of the catabolic compartment in 
VTRNA1-1 KO cells is indicated by the increased glycosyla-
tion of LAMP1 in untreated growth conditions (Figure 2C). 
Concurrently, VTRNA1-1 depletion was indeed able to induce 
a clear switch of the lysosome intralumenal pH toward a more 
alkaline environment, affecting the catabolic and proteolytic 
activity (Figure 2E). These findings seem to attribute the 
autophagosomes accumulation evident in VTRNA1-1 KO 
cells to the lysosomal compartment dysfunction.
The expression and activity of the lysosomal components 
are tightly coordinated to allow it to function under phy-
siological and pathological conditions by the CLEAR genes 
network, as well as by TFEB nuclear translocation and 
transcriptional control [54]. Investigating the potential 
cause for the compromised lysosomal function, we uncov-
ered that TFEB nuclear translocation was decreased in 
VTRNA1-1 KO cells, with a significant downregulation of 
the CLEAR network genes in vitro and in vivo (Figure 3C- 
F). Genetic complementation of VTRNA1-1 in KO cells 
restored not only cellular proliferation (Figure 1A, C) but 
also CLEAR gene expression (Figure 3E), further suggesting 
their interdependence with VTRNA1-1 levels. Given the 
well-known tight link between the MAPK pathway and 
TFEB activation [39], we found that VTRNA1-1 depletion 
markedly induced an increased phosphorylation of the 
downstream effector of the MAPK kinase cascade 
MAPK1/3 (Figure 3B), which finally suggested that 
VTRNA1-1 KO triggers a compensatory overactivation of 
the MAPK pathway (Figure 5). Similarly, in HeLa cells we 
recently demonstrated that deletion of VTRNA1-1, but not 
of the paralog VTRNA1-3, modulated several signaling 
pathways, including the MAPK cascade [13]. The link 
between vault RNA expression and MAPK signaling was 
recently substantiated in cultured mouse cortical neurons 
[55]. Further, we demonstrated that all these phenomena 
reported here can potentiate the antitumor effect of con-
ventional chemotherapeutic drugs. Specifically, the vast 
majority of chemotherapeutic agents, due to their hydro-
phobic and weak base chemical characteristics, often get 
passively sequestered within the acidic lumen of lysosomes, 
becoming unable to reach their intracellular molecular tar-
get [56]. Interestingly, the lack of VTRNA1-1 and the con-
sequently elevated alkaline lysosomal pH lead to 
a diminished cytotoxicity of the lysosomal disruptor 
LLOMe, mainly due to its decreased lysosomotropism 
(Figure S4). On the other hand, the similarly reduced 
lysosomotropism of sorafenib observed in the KO cells 
in vitro and in vivo revealed an increased availability of 
sorafenib at its target site and therefore a stronger antitu-
mor effect (Figure 4C).
Taken together, our study uncovered the involvement 
of VTRNA1-1/vtRNA1-1 in tumor cell proliferation and 
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tumorigenesis, demonstrating its crucial role to maintain 
the catabolic compartment and chemoresistance (Figure 
5). This novel pro-survival function may identify 
vtRNA1-1 as a new therapeutic target to overcome 
chemo-insensitivity caused by passive lysosomal seques-




Huh-7 (kindly provided by Matthias Hentze; EMBL, 
Heidelberg, Germany) and HeLa cells (ATCC®-CCL-2™) 
were cultured in low glucose (5 mM) DMEM (Thermo 
Fisher, 21,331,046) supplemented with 10% heat inactivated 
FBS (10,082,147, Thermo Fisher) and 100 U/ml PenStrep 
glutamine (Thermo Fisher, 10,378,016). The VTRNA1-1 KO 
and WT Huh-7 cell lines were kindly provided by 
M. Hentze (EMBL, Heidelberg, Germany). We derived 
a Huh-7 VTRNA1-1 complementation cell line using lenti-
viral transduction (below) in the Huh-7 KO cells. After 
successful lentiviral transduction, positively infected cells 
were selected by treating them with 1 μg/ml puromycin 
for at least 1 week. Single cell clones were obtained by serial 
dilution. Normal liver tissue was obtained from surgical 
resections from consented patients at the University 
Hospital of Bern. Hepatocytes were then isolated by enzy-
matic perfusion as previously described [57] and kept in 
culture at 37°C in a humidified incubator with 5% of CO2.
Patient-derived tissues
Primary human liver tissue for hepatocyte isolation [57] and 
HCC tumors from liver were obtained from patients of the 
University Hospital Bern (Inselspital). Informed consent was 
obtained prior to surgery in compliance with the local ethics 
regulations and under approval of local ethics commission 
(Project-ID Nr. 2019–00157).
Lentiviral transduction
Lentiviral particles were generated in human HEK 293 T cells 
(kindly provided by M. Ruepp, King’s College London), which 
were transiently transfected with lentiviral plasmids containing 
cDNAs coding for VTRNA1-1, together with the packaging 
plasmids pSPAX and the envelope plasmid pVSV-G (kindly 
provided by S. Geley, Medical University Innsbruck). After 
48 h and 72 h lentiviral supernatant was collected, sterile filtered 
(Sigma-Aldrich, Whatman Puradisc FP30, 0.2 mM) and supple-
mented with polybrene (Sigma, 107,689) to a final concentra-
tion of 4 μg/ml and added to the target cells overnight.
Transfection and treatments
Transfections were done using Lipofectamine 3000 (Thermo 
Fisher, L3000008) for plasmid DNA. Doxorubicin (Sigma- 
Aldrich, D1515) was diluted in water to 5 mM and used at 
1 μM for 48 h. Bafilomycin A1 (BafA; Sigma-Aldrich, B1793) 
was diluted in DMSO to 200 μM and used at 100 nM for 4 h. 
Chloroquine (CQ; Sigma-Aldrich, C6628) was diluted in DMSO 
to 50 mM and used at 20 μM for 4 h. Rapamycin (Sigma-Aldrich, 
R0395) was diluted in ethanol to 2 mM and used at 200 nM for 
4 h. Leu-Leu methyl ester hydrobromide (LLOMe; Sigma- 
Aldrich, L7393) was diluted in DMSO to 1 M and used from 
0.001 to 1.4 mM for 6 h. Sorafenib tosylate (MedChemExpress, 
HY-10201A) was used from 5 to 14 μM for 24 h in vitro and 100  
mg/kg in vivo daily. FITC-dextran (Sigma-Aldrich, FD40S) was 
directly diluted in the medium to 0.1 mg/mL. MTT (Thermo 
Fisher, M6494) was diluted in PBS (137 mM NaCl, 2.7 mM KCl, 
12.5 mM Na2HPO4, 1.8 mM KH2PO4, pH 7.4) to 5 mg/mL. For 
high starvation, cells were washed twice with PBS and starved in 
low glucose DMEM lacking amino acids (USBiological, D9800- 
13) and serum. To overexpress the TFEB variant with pro-
nounced nuclear localization characteristics [45] the plasmid 
pCIP-caTfeb (Addgene, 79,013; deposited by Reuben Shaw) 
was transfected into Huh-7 VTRNA1-1 KO cells.
Cell proliferation and viability assay
Cell proliferation was detected using 3-(4,5-dimethylthazol-2-yl)- 
2,5-diphenyltetrazolium bromide (MTT; Thermo Fisher, M6494) 
or via automated cell counting. For the MTT assay approxi-
mately 5 x 103 and 1.5 × 104 cells/well, for proliferation or 
viability respectively, were seeded into 96-well plates and allowed 
to attach overnight. After 24, 48, 72 and 96 h, cell viability was 
assessed using MTT assay. The MTT solution (5 mg/mL) was 
added to each well for 3 h. The resulting formazan crystals were 
dissolved in DMSO and the optical density was measured at 570  
nm using a Tecan infinite M1000Pro plate reader. Three inde-
pendent experiments were conducted in triplicates. To assess 
proliferation rates via automated cell counting, 1 × 105 cells/ 
well were seeded on 6 well plates. After 24 h, 48 h and 72 h 
cells were washed twice with PBS, detached using trypsin and 
counted using a TC10™ Automated Cell Counter (Bio-Rad).
Colony formation assay
Approximately 5 × 102 cells were placed in a 6-well plate in 
DMEM containing 10% FBS for 2 weeks. Colonies were 
fixed with methanol and stained with 0.1% crystal violet in 
20% methanol for 30 min. Each assay was conducted in 
triplicate.
RNA extraction and quantitative real-time RT-qPCR 
(qPCR)
RNA was isolated from cells as well as tissue samples by 
Tri-reagent (Zymo Research, R2050-1-200) following the 
manufacture’s protocol. Reverse transcription (RT) of 
total RNA was carried out using SuperScript™ IV One- 
Step RT-PCR System (Invitrogen, 18,090,010), according 
to the manufacturer’s protocol, using random primer 
hexamers for cDNA amplification. Subsequent quantita-
tive PCR (qPCR) on the cDNA was carried out using 
GoTaq® qPCR Master Mix (Promega, A6002), according 
to the manufacturer’s protocol (Table S1 lists the used 
primers). The QIAgility robot was used to pipette all the 
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reagents into the qPCR reactions and qPCR amplification 
was carried out using Rotor Gene 6000 (QIAGEN), 
according to the manufacturer’s instructions. qPCR ana-
lyses were done in Roboticx software (QIAGEN), and 
differential mRNA transcript abundances were calculated 
using the ΔΔCt method as described [58].
Northern blot
2–10 µg total RNA was separated on an 8% denaturing poly-
acrylamide gel (7 M Urea, in 1x TBE buffer). The gel was 
subsequently electroblotted onto a nylon membrane 
(Amersham Hybond N+; GE Healthcare, RPN203B) as 
described [59]. The membranes were hybridized using 
32P-labeled probes listed in Table S1 and exposed to phos-
phorimaging screens. An autoradiogram was developed using 
a Typhoon FLA1000 phosphorimager.
Western blot
Total protein cell lysates were obtained using RIPA buffer 
(10 mM Tris/Cl, pH 8, 1 mM EDTA, 1% Triton X-100 
[Sigma-Aldrich, T8787], 0.1% deoxycholate [Sigma-Aldrich, 
D6750], 0.1% SDS, 140 mM NaCl) containing protease inhi-
bitor cocktail (Sigma-Aldrich, 11,697,498,001), phosphatase 
inhibitors (Thermo Scientific, A32957) and 0.5% NP-40 
(Sigma-Aldrich, 56,741). For nuclear-cytoplasmic fractiona-
tion, cells were treated as described previously [60] . 
Western blots were performed according to standard proto-
cols using the antibodies listed in Table 1.
GST-assay
Huh-7 and HeLa cells were transiently transfected with the 
GST-BHMT plasmid as previously shown by Mercer et al. 
[61]. Briefly, BHMT transfected cells were cultured in starva-
tion DMEM medium lacking the essential amino acids (Arg, 
Cys, His, Ile, Leu, Lys, Met, Phe, Thr, Trp, Tyr, and Val) 
(USBiological, D9800-27) and FBS for 6 h in the presence of 
E64d (6 mM; Sigma-Aldrich, E8640-250UG) and leupeptin 
(11 mM; Sigma-Aldrich, L-0649). Afterward, proteins from 
the cells were extracted with RIPA buffer. Total protein of cell 
extracts was determined by Bradford method 
(ThermoScientific, 23,227) and GST-BHMT was precipitated 
with glutathione agarose (Sigma, G4510). Precipitates were 
then mixed in SDS-PAGE sample buffer, resolved by 
SDS-PAGE and visualized by western blotting and 
chemiluminescence.
Lysosomal pH measurements by flow cytometry
Lysosomal pH measurements were based on an adjusted pro-
tocol recently published by Gavini et al [37]. In brief, HCC 
cell lines were seeded and cultured in cell culture medium 
containing FITC-Dextran (0.1 mg/mL; Sigma-Aldrich, 
FD40S) for three days. After this period FITC-Dextran was 
removed by aspirating the medium and fresh cell culture 
medium was added with the respective treatments as indi-
cated. Lysosomal pH from samples belonging to the standard 
curve scale (pH ranging from 4 to 6) and experimental-treated 
ones were analyzed by FACS. Triplicate samples were taken 
for each condition analyzed.
Subcutaneous HCC cell line xenograft mouse models
Eight- to 12-week-old male rag2−/- il2rg/γc−/- mice (in house 
breeding) were used for the subcutaneous xenograft model. 
2 × 106 HCC cells were injected in a 1:1 ratio with Matrigel® 
(BD Biosciences, 356,234). HCC patient-derived specimens 
were transplanted subcutaneously. Tumor volume was mea-
sured using a digital caliper thanks to a modified ellipsoid 
formula: volume = (4/3) × π × (length/2) × (width/2) × 
(height/2). Upon reaching a volume of 250 mm3, animals 
were randomly divided into different groups as described: 
administration of the vehicle (50% Cremophor EL and 50% 
ethyl alcohol mixture at 12–24 mg/mL – control group and 
sorafenib (100 mg/kg) daily by oral gavage. The tumor 
volume and the body weight were recorded every second 
day for fourteen days. At the end of experiment, the entire 
tumor was carefully removed, and some snap-frozen samples 
were stored in liquid nitrogen and kept at −80°C until further 
use. Other parts of the tissue were fixed in 4% formaldehyde 
for histological analysis. All animal experiments were con-
ducted in accordance to Swiss Guidelines of Care and Use 
of Laboratory Animals.
Immunohistochemistry
Tissue samples were fixed in 4% formaldehyde, processed, 
embedded in paraffin and sectioned with Leica Microtome. 
Sections were stained using MKI67/Ki67 antibody (Abcam, 
ab16667). For each sample five randomly chosen fields were 
imaged by Leica camera and analyzed by ImageJ software. 
Coverslips were mounted with VECTASHIELD Antifade 
Mounting Medium and images were taken using an auto-
mated inverted microscope (Leica DMSI4000 B).
Table 1. Antibodies used in this study.
Antibody Source Identifier




Cell Signaling Technology 9911
GAPDH Cell Signaling Technology 2118S
GST (B-14) Santa Cruz Biotechnology sc-138
LAMP1 Santa Cruz Biotechnology sc-17,768
LC3 Novus Biologicals NB600-1384
MAP2K1/MEK1- 
MAP2K2/MEK2
Cell Signaling Technology 9911
MTOR Cell Signaling Technology 2983S
MKI67/Ki67 Abcam ab16667
SQSTM1/p62 Cell Signaling Technology 8025S
RPS6KA/p90RSK Cell Signaling Technology 9911
PARP1 Santa Cruz Biotechnology sc-8007
p-MTOR Cell Signaling Technology 5536S
TFEB Cell Signaling Technology 4240
Histone H3 Millipore 06–570
TUBA4A/α-tubulin Sigma Aldrich T6074
TFE3 Proteintech 14,480-1-AP
MITF Proteintech 13,092-1-AP
anti-rabbit IgG, HRP linked Cell Signaling Technology 7074S
anti-mouse IgG, HRP linked Dako P0260
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Statistical analysis
Images were quantified with ImageJ. Data are displayed as 
mean ± SD or SEM; Student’s t test was used; n values are 
indicated in the respective Figure legends. p-values are indi-
cated in the Figure, p < 0.05 was considered statistically. 
GraphPad Prism v8 was used to create plots.
Abbreviations
ATP6V0D2: ATPase H+ transporting V0 subunit d2; BafA: bafilomycin 
A1; CLEAR: coordinated lysosomal expression and regulation; CQ: chlor-
oquine; DMSO: dimethyl sulfoxide; GST-BHMT: glutathionine 
S-transferase N-terminal to betaine–homocysteine S-methyltransferase; 
HCC: hepatocellular carcinoma; LAMP1: lysosomal associated mem-
brane protein 1; LLOMe: L-leucyl-L-leucine methyl ester; MAP1LC3B/ 
LC3: microtubule associated protein 1 light chain 3 beta; MAPK: mito-
gen-activated protein kinase; MITF: melanocyte inducing transcription 
factor; MTT: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide; ncRNA: non-coding RNA; RNP: ribonucleoprotein; SF: sorafenib; 
SQSTM1/p62: sequestosome 1; STS: staurosporine; tdRs: tRNA-derived 
RNAs; TFE3: transcription factor binding to IGHM enhancer 3; TFEB: 
transcription factor EB; vtRNA: vault RNA transcript.
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